# Psilocybin research and therapeutic outcomes

> Live situation record from CLSTR: https://clstr.news/situations/psilocybin-research-and-therapeutic-outcomes
> Updated: 2026-08-23T12:01:00.000Z. Sources: 10. Developments: 3.

Research into psilocybin has transitioned from exploring microdosing protocols and observational links to evaluating structured, state-regulated therapeutic programs. Initial reports focused on microdosing guides, such as the Fadiman schedule, which suggest sub-perceptual doses for enhancing creativity and mood, though researchers noted that clinical evidence remains limited. Observational studies also suggested a correlation between occasional psilocybin use during alcohol consumption and fewer depressive symptoms, though causality was not proven. Subsequent findings from Oregon’s state-regulated psilocybin program provided more specific clinical data. A study published in JAMA Network Open regarding 346 adults receiving services at licensed centers between November 2024 and March 2026 showed significant declines in moderate-to-severe symptoms: depression fell from 42.2% to 16.5%, anxiety from 45.1% to 13.2%, and PTSD symptoms from 48% to 16.8%. Life satisfaction also rose from 63% to over 82% within three months. The program was described as generally safe, with serious adverse reactions occurring in approximately 1.2% of participants (four individuals) who required medical attention for behavioral reactions. Nearly 59% of participants ranked the experience among the “top ten most significant experiences of their lives.” In Australia, where psilocybin was approved for treatment-resistant depression in 2023, patient access remains low, with approximately 65 patients accessing therapy in 2025. High costs, ranging from $15,000 to $30,000 per session, remain a major barrier, though regulations requiring a psychiatrist’s presence were recently relaxed to reduce expenses. Recent clinical research has expanded into treating addiction and eating disorders. In the United Kingdom, Imperial College London researchers reported that 18 out of 21 women with anorexia nervosa showed a reduction in eating disorder scores following six weeks of psilocybin administration paired with intensive psychotherapy; nearly half maintained scores comparable to those without eating disorders after one year.

## Timeline

### 2026-08-23: Psilocybin research shows potential for treating addiction and eating disorders

Clinical trials are showing promise for psilocybin in treating anorexia, cocaine addiction, and depression, though high costs and difficulties in placebo-controlled testing remain significant hurdles.

5 sources. https://clstr.news/cluster/psilocybin-research-explores-therapeutic-potential-for-mental-health

### 2026-08-19: Oregon psilocybin program linked to improved mental health outcomes

A study of Oregon’s regulated psilocybin program shows significant reductions in depression, anxiety, and PTSD symptoms among participants, with reported high levels of safety and life satisfaction.

5 sources. https://clstr.news/cluster/oregon-psilocybin-program-linked-to-improved-mental-health-outcomes

### 2026-08-01: Psilocybin Studies Show Microdosing Guide and Alcohol-Linked Mood Benefits

Guides detail psilocybin microdosing protocols, while a U.S. study links occasional mushroom use with lower depression among drinkers, though causality remains unproven.

2 sources. https://clstr.news/cluster/psilocybin-studies-show-microdosing-guide-and-alcohol-linked-mood-benefits

---
Cite as: Psilocybin research and therapeutic outcomes. CLSTR, https://clstr.news/situations/psilocybin-research-and-therapeutic-outcomes